The positive Phase 2a data and clean safety profile represent a significant de-risking of bempikibart, likely driving a strong near-term rally. Monitor the upcoming medical meeting presentations and initiation of the registrational program in H1 2027. The debt payoff removes balance sheet overhang, but the company will likely need additional financing to fund the registrational trial.
Price Chart
Executive Summary
Q32 Bio reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata, showing a 35.3% mean reduction in SALT score and 40% SALT-20 response in the mITT population with a favorable safety profile. The company also disclosed it paid off the remaining ~$6.8M loan from Silicon Valley Bank, eliminating debt. The data supports advancement to a registration-directed program in H1 2027, a significant milestone for this clinical-stage biotech.
Key Facts
- Mean SALT score reduction of 35.3% in mITT population at Week 36
- 40.0% (10/25) of mITT patients achieved SALT-20 (80% scalp hair coverage) at Week 36
- 30.3% (10/33) of ITT patients achieved SALT-20
- 44.0% (11/25) mITT achieved both SALT30 and SALT50 responses
- No serious adverse events or Grade 3+ treatment-related adverse events observed
- Injection site reactions were the most common TEAE (36.3%) but were mild and self-resolving
- Company intends to advance bempikibart into a registration-directed program in first half of 2027
- Paid off remaining ~$6.8M loan from Silicon Valley Bank on June 24, 2026, terminating the Loan Agreement
Financial Impact
No revenue for this clinical-stage company. Positive Phase 2a data de-risks lead asset (bempikibart) in alopecia areata, a ~700,000-patient US market. Debt elimination (~$6.8M) improves balance sheet.
Risk Factors
- Open-label, single-arm design with small sample (n=33) limits data robustness
- Durability data beyond Week 36 off-drug follow-up is still immature
- Registrational trial execution and potential regulatory hurdles ahead
- Competition from JAK inhibitors and other emerging therapies for alopecia areata
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301464 |
| Document: d142528dex991.htm | 0001193125-26-301464 |
| Document: 0001193125-26-301464-index-headers.html | 0001193125-26-301464 |
| Document: 0001193125-26-301464-index.html | 0001193125-26-301464 |
| Document: 0001193125-26-301464.txt | 0001193125-26-301464 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access